Jenna Philpott, Author at Clinical Trials Arena

Cofactor’s cancer biomarker test outshines standard ICI predictive tests

Jenna Philpott — Fri, 08 Nov 2024 11:32:10 +0000

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with chemotherapy.

Jenna Philpott — Thu, 07 Nov 2024 16:03:29 +0000

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

Jenna Philpott — Wed, 06 Nov 2024 14:55:54 +0000

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to gauge impact.

Jenna Philpott — Tue, 05 Nov 2024 12:10:52 +0000

J&J inherited the Javelin catheter as part of its $13.1bn acquisition of Shockwave Medical which completed in June 2024.

Jenna Philpott — Mon, 04 Nov 2024 17:44:25 +0000

In an end-of-Phase II meeting, the FDA indicated support for accelerated approval based on existing clinical data.

Jenna Philpott — Mon, 04 Nov 2024 16:22:13 +0000

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week treatment period.

Jenna Philpott — Fri, 01 Nov 2024 14:03:32 +0000

The role of emerging digital tools and AI were at the forefront of a panel discussion at the Outsourcing in Clinical Trials DACH 2024 conference.

Jenna Philpott — Fri, 01 Nov 2024 11:29:38 +0000

The data was shared at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, on 31 October.

Jenna Philpott — Thu, 31 Oct 2024 13:20:29 +0000

Alzheimer’s patients using the SinaptiStim system experienced a 44% reduction in disease progression over 12-months.

Jenna Philpott — Thu, 31 Oct 2024 13:07:07 +0000

The WHO’s senior advisor of R&D Vasee Moorthy discussed the new framework for clinical trials at the OCT DACH 2024 conference in Zurich.